2991427-09-7
2991427-09-7
Chemical Structure
HDAC6-IN-23
- CAS No.: 2991427-09-7
- Formula:C15H10F2N8O
- Molecular Weight:356.29
InChIKey: ZTVLPDLCENUSAG-UHFFFAOYSA-N
SMILES: FC(F)C(O1)=NN=C1C(C=N2)=CC=C2CN3N=NC(C4=NC=CC=C4)=N3
Biological Activity: HDAC6-IN-23 (compound 9) is an orally active HDAC6 inhibitor[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
HDAC6-IN-23 | 99.61% | HDAC6-IN-23 (compound 9) is an orally active HDAC6 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC-IN-58 | HDAC-IN-58 is a HDAC inhibitor. HDAC-IN-58 has HDAC6-specific inhibition activity with an IC50 value of 2.06 nM. HDAC-IN-58 can be used for the research of chronic diseases, including neurodegenerative and psychiatric conditions. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC6-IN-26 | 99.41% | HDAC6-IN-26 (compound 23) is a potent inhibitor of HDAC6. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mycobacterium Tuberculosis-IN-2 | Mycobacterium Tuberculosis-IN-2 (Compound 29) is a bacterial inhibitor that effectively inhibits Mycobacterium Tuberculosis. Mycobacterium Tuberculosis-IN-2 can be used in tuberculosis research (MIC = 0.07-0.16 μM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC6-IN-33 | 98.96% | HDAC6-IN-33 (compound 6) is a selective and irreversible HDAC6 inhibitor with an IC50 of 193 nM. HDAC6-IN-33 shows no activity against HDAC1-4. HDAC6-IN-33 is a tight-binding HDAC6 inhibitor capable of inhibiting HDAC6 via a two-step slow-binding mechanism. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SE-7552 | 98.79% | SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM. SE-7552 is greater than 850-fold selectivity versus all other known HDAC isozymes. SE-7552 is capable of blocking multiple myeloma growth in vivo. SE-7552 acts as an anti-obesity agent in diet-induced obese mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ITF5924 | ITF5924 (compound 1) is a potent and highly selective HDAC6 inhibitor with an IC50 of 7.7 nM. ITF5924 shows greater than 104-fold selectivity for HDAC6 over all other HDAC subtypes. ITF5924 containing a difluoromethyl-1,3,4-oxadiazole (DFMO) moiety is slow-binding substrate analog of HDAC6 that undergo an enzyme-catalyzed ring opening reaction, forming a tight and long-lived enzyme-inhibitor complex. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
E234G HYPE-IN-1 | E234G HYPE-IN-1 (Compound I2.10) is an inhibitor of AMPylation directed by the Huntingtin-interacting protein E (HYPE), possessing low micromolar bioactivity, low cytotoxicity, and blood-brain barrier permeability. E234G HYPE-IN-1 can inhibit the AMPylation of B-cell immunoglobulin-binding protein (BiP), the primary substrate of HYPE. E234G HYPE-IN-1 is suitable for development as a HYPE-specific therapeutic agent for clinical conditions such as neurodegenerative diseases and diabetes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
HDAC6-IN-78 | HDAC6-IN-78 (Example 48) is a selective HDAC6 inhibitor with an IC50 of 24 nM. HDAC6-IN-78 shows no activity against other HDAC isoforms. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Casein kinase 1δ-IN-14 | Casein kinase 1δ-IN-14 (compound 481) is a casein kinase inhibitor that can be used to study neurodegenerative diseases such as Alzheimer's disease. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2,4-Di(pyridin-2-yl)-6-(pyridin-3-yl)pyrimidine | 2,4-Di(pyridin-2-yl)-6-(pyridin-3-yl)pyrimidine is a metal-organic framework (MOF). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
